Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penfluridol versus second-generation oral antipsychotics in psychotic disorders
2014-003834-21Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of penfluridol, olanzapine and risperidone in Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Time to all-cause medication discontinuation. Started Apr 2015; status: terminated.
02
Drugs
penfluridololanzapinerisperidone
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2014-003834-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003834-21.